SCHEMBL15095046

SCHEMBL15095046

N#Cc1cc(Br)cc(C(=O)Nc2cccc(-c3nnn[nH]3)c2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.41
▸ TP53 P04637 2/20 0.41
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ LCLAT1 Q6UWP7 1/20 0.41
▸ MAOA P21397 1/20 0.41
▸ MAOB P27338 1/20 0.41
▸ MEN1 O00255 2/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ KDM4E B2RXH2 1/20 0.40
▸ NPC1 O15118 1/20 0.40
▸ POLB P06746 1/20 0.40
▸ THRB P10828 1/20 0.40
▸ RECQL P46063 1/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ ATM Q13315 1/20 0.40
▸ MMP2 P08253 1/20 0.39
▸ MMP9 P14780 1/20 0.39
▸ COMT P21964 1/20 0.39
▸ MMP8 P22894 1/20 0.39
▸ MMP13 P45452 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15094758 0.87 RXFP1 (0.48) MAOAMAOB
SCHEMBL16340990 0.85 RAB9A (0.44) MAPTTP53SMN1; SMN2LCLAT1MEN1
SCHEMBL31125137 0.78 MAPT (0.59) MAPTSMN1; SMN2MEN1KMT2AKDM4E
SCHEMBL31680549 0.77 MMP2 (0.54) MAPTSMN1; SMN2LCLAT1MEN1KMT2A
SCHEMBL25159969 0.76 F2 (0.51) TP53MEN1KMT2ANPC1RAB9A
SCHEMBL15094744 0.76 KMT2A (0.49) MAPTSMN1; SMN2MEN1KMT2AKDM4E
SCHEMBL21067860 0.76 KMT2A (0.58) MAPTTP53SMN1; SMN2MEN1KMT2A
Water SCHEMBL9417276 0.75 NR1H4 (0.43) MAPTTP53SMN1; SMN2MEN1KMT2A
SCHEMBL22167182 0.75 MGLL (0.54) MAPTMEN1KMT2A
SCHEMBL21812212 0.74 MAOA (0.54) MAPTSMN1; SMN2MAOAMAOBMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10604493-B2 Compositions, methods of use, and methods of treatment UNIVERSITY OF SOUTH FLORIDA (US) 2020-03-31 — — US claimed
US-10604493-B2 Compositions, methods of use, and methods of treatment UNIVERSITY OF SOUTH FLORIDA (US) 2020-03-31 — — US disclosed
US-20170088524-A1 Compositions, Methods of Use, And Methods of Treatment UNIVERSITY OF SOUTH FLORIDA 2017-03-30 — — US disclosed
US-9556131-B2 Compositions, methods of use, and methods of treatment UNIVERSITY OF SOUTH FLORIDA (US) 2017-01-31 — — US disclosed
US-20140378516-A1 COMPOSITIONS, METHODS OF USE, AND METHODS OF TREATMENT UNIVERSITY OF SOUTH FLORIDA 2014-12-25 — — US disclosed
EP-2800568-A1 COMPOSITIONS, METHODS OF USE, AND METHODS OF TREATMENT University Of South Florida (US) 2014-11-12 — — EP disclosed
WO-2013103760-A1 COMPOSITIONS, METHODS OF USE, AND METHODS OF TREATMENT UNIVERSITY OF SOUTH FLORIDA (US) 2013-07-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140378516-A1 COMPOSITIONS, METHODS OF USE, AND METHODS OF TREATMENT LIPA, LCT, GAA MAPT 2458/4885TP53 2502/4885SMN1; SMN2 789/4885
US-10604493-B2 Compositions, methods of use, and methods of treatment LIPA, LCT, GAA MAPT 2458/4885TP53 2502/4885SMN1; SMN2 789/4885
US-20170088524-A1 Compositions, Methods of Use, And Methods of Treatment LIPA, LCT, GAA MAPT 2458/4885TP53 2502/4885SMN1; SMN2 789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback